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Abstract The relationship between hypertrophy, perfu-
sion abnormalities and fibrosis is unknown in young patients
with hypertrophic cardiomyopathy (HCM). Since mounting
evidence suggests causal relationship between myocardial
ischemia and major adverse cardiac events, we sought to
investigate whether (1) regional myocardial perfusion is
decreased in young HCM patients and in individuals at risk
of HCM, and (2) hypoperfused areas are larger than areas
with fibrosis. HCM patients (n = 12), HCM-risk subjects
(n = 15) and controls (n = 9) were imaged on a 1.5 T MRI
scanner. Myocardial hypertrophy was assessed on cine
images. Perfusion images were acquired during adenosine
hyperemia and at rest. Maximum upslope ratios of perfusion
(stress/rest) were used for semiquantitative analysis. Fibrosis
was assessed by late gadolinium enhancement (LGE).
Results are presented as median and range. Perfusion in
HCM-risk subjects and in non-hypertrophied segments in
HCM patients showed no difference compared to controls
(P = ns). Hypertrophic segments in HCM patients without
LGE showed decreased perfusion compared to segments
without hypertrophy [1.5 (1.1–2.3) vs. 2.0 (1.8–2.6),
P\ 0.001], and hypertrophic segments with LGE showed
even lower perfusion using a segmental analysis [0.9
(0.6–1.8), P\ 0.05]. The extent of hypoperfused myo-
cardium in HCM patients during adenosine exceeded the
extent of fibrosis on LGE [20 (0–48) vs. 4 (0–7) % slice area,
P\ 0.05] and hypoperfused areas at rest (P\ 0.001).
Regional perfusion is decreased in hypertrophied compared
to non-hypertrophied myocardium and is lowest in fibrotic
myocardium in young HCM patients but does not discrimi-
nate HCM-risk subjects from controls. The stress-induced
hypoperfused regions exceed regions with LGE, indicating
that hypoperfusion precedes fibrosis and may be a more
sensitive marker of diseased myocardium in HCM.
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Introduction
Hypertrophic cardiomyopathy (HCM) is the most common
inherited cardiac disease affecting one person in 500 and
usually manifests in young adulthood [28]. Several genetic
mutations, mainly of proteins coding of the cardiac sar-
comere [26], have been linked to HCM. Patients with HCM
can present with various symptoms ranging from dyspnea,
palpations and fatigue to sudden cardiac death due to
malignant arrhythmias [8, 9]. Therefore, identification of
young patients with subclinical HCM and patients at risk of
HCM is important. The morphological hallmarks of HCM
are left ventricular (LV) diastolic failure due to hypertro-
phy and stiffening of the myocardium, decreased myocar-
dial perfusion and fibrosis [2, 17, 35]. Cardiovascular
magnetic resonance (CMR) has the ability to assess both
LV thickness and volumes [25], presence of ischemia using
stress CMR [35] and hyperenhancement on LGE-CMR
[33], which has been shown to correspond to fibrosis in
HCM [31]. The mechanisms and relation of the develop-
ment of hypoperfused areas and fibrosis are, however, not
fully understood. The genetic defect may cause a direct
collagen deposition in the myocardium and vasculature
causing hypoperfusion and myocardial fibrosis [16, 38]. An
alternative hypothesis is that hypoperfusion occurs first
with subsequent replacement fibrosis [4, 32]. The prog-
nostic value of LGE in HCM remains elusive [11, 18], and
ischemia has been proposed as an earlier marker of disease
[4, 29, 32]. We have earlier showed that global perfusion is
decreased in the same cohort of young patients with HCM
investigated in the current study [12]. However, the rela-
tionship between regional perfusion, hypertrophy and
fibrosis has not been studied in young HCM patients and
HCM-risk subjects. An important question is whether these
changes are present already at the very early stage of the
disease, i.e., before the onset of myocardial hypertrophy.
Therefore, the aim of this study was to (1) measure if
regional perfusion is decreased in young patients with
HCM and in HCM-risk subjects and (2) determine whether
hypoperfused areas are larger than areas with fibrosis.
Materials and Methods
Study Population
The study protocol conforms to the ethical guidelines of the
Declaration of Helsinki and was approved by the Regional
Ethical Review Board. Written informed consent was
obtained from all subjects or, for subjects under 18 years of
age, from their parents or legal guardians.
Patients\30 years of age were identified and recruited
at the Departments of Pediatric and Adult Cardiology and
referred for a CMR examination. Study participants were
defined as either HCM patients or HCM-risk subjects upon
inclusion using the following criteria: (1) HCM: if the
patient had an interventricular septum (IVS) and/or poste-
rior wall (PW) thickness exceeding 13 mm (subjects
[18 years of age) or [3 SD on Z-score (pediatric
patients) on echocardiography with confirmed
increased wall thickness and/or fibrosis on CMR, (2)
HCM-risk: if the subject had either a HCM gene
mutation or first-degree relatives with HCM, but
without signs of LV hypertrophy or fibrosis on CMR.
Genetic testing was done according to guidelines by
the clinic, and information of the HCM-causing
mutation was collected from the medical record.
Healthy age- and gender-matched controls (no history
of cardiac disease, hypertension and normal 12-lead
electrocardiogram) were also included.
Exclusion criteria were as follows: LV outflow tract
obstruction, LV hypertrophy (LVH) due to other causes
including congenital heart disease, malformation syn-
dromes, neuromuscular and metabolic disorders. Subjects
with contraindications for CMR were not enrolled. Typical
contraindications for adenosine, which was used as a stress
agent, such as allergic asthma and high-degree AV block,
were followed. However, subjects not eligible for adeno-
sine were included in the rest of the CMR protocol. All
subjects were asked to refrain from caffeine 24 h prior to
the CMR examination.
Imaging Protocol
All CMR imaging was performed on a 1.5 T scanner
(Philips Achieva, Best, The Netherlands) using a
32-channel coil. LV function was assessed by cine imaging
using a steady-state free precession sequence (SSFP) in
breath hold both in short-axis and long-axis projections (2-,
3- and 4-chamber views).
Regional Perfusion
Regional perfusion imaging was performed with a bal-
anced turbo fast-field echo (TFE) sequence in breath hold
(TR 2.7, TE 1.4, a 50, acquired spatial resolution
2 9 2 9 10 mm reconstructed to 1.4 9 1.4 9 10 mm and
SENSE factor 3). Images were acquired during the first
pass of a bolus of a gadolinium (Gd)-based contrast agent
(Dotarem, 0.05 mmol/kg, injection rate 5 ml/s) followed
by a saline flush (injection rate 5 ml/s). Perfusion images
were acquired in three short-axis slices at basal,
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midventricular and apical levels. Images were acquired
during adenosine (140 lg/kg/min) hyperemia and at rest
10 min after terminating the adenosine infusion.
Late Gadolinium Enhancement
LGE-CMR images were acquired with a 3D inversion
recovery gradient echo (IR GRE) sequence mid-diastole
during end-expiratory breath hold. Short-axis slices cov-
ering the entire LV from base to apex and three long-axis
projections were collected 10–20 min after administration
of an additional 0.1 mmol/kg of Dotarem after the resting
perfusion. Typical image parameters were as follows: five
slices per breath hold reconstructed with no slice gap, slice
thickness 8 mm and inplane resolution 1.5 9 1.5, echo
time 1.3 ms, effective repetition time every heartbeat, flip
angle 15 and inversion time 220–280 ms.
Image Analysis
The software Segment v1.9 (http://segment.heiberg.se) was
used for all image analysis [14].
Left Ventricular Dimensions
Left ventricular mass (LVM), global LV function and
regional end-diastolic LV wall thickness were determined
by first manually delineating the endocardium and epi-
cardium in short-axis cine images at both end-systole and
end-diastole. LVM was calculated by multiplying the
myocardial volume measured by planimetry with the
myocardial density (1.05 g/ml). The following LV indices
were determined from the planimetric short-axis cine
measurements: end-diastolic volume (EDV), end-systolic
volume (ESV), stroke volume (SV) and ejection fraction
(EF). The maximum end-diastolic wall thickness was
measured in the IVS and PW in two short-axis slices.
Regional Perfusion
First-pass-perfusion images were delineated by semiauto-
matically tracing the endocardium and epicardium in all
time frames during the first pass of the contrast bolus. The
slices were divided according to the American Heart
Association (AHA) 17-segment model with the apex being
left out, yielding a maximum of 16 segments per subject
with six basal, six midventricular and four apical segments.
The delineated contours were contracted by 10 % both
endo- and epicardially to account for partial volume and
interaction with the blood pool. A semiquantitative mea-
surement of maximum upslope ratio was used to assess the
perfusion and was calculated as the ratio of perfusion stress
and rest values normalized for the arterial input function in
the LV blood pool [19]. In order to calculate maximal
upslope, a linear curve fitting was applied automatically in
a plugin to the software used.
Furthermore, co-registration between cine, LGE-CMR
and perfusion short-axis images was performed in order to
identify segments that were hypertrophied (LVH?) or of
normal wall thickness (LVH-), hyperenhanced on LGE
(LGE?) or not (LGE-). The upslope analysis was per-
formed on a segmental basis and also on a per subject level
by averaging all segments with the same tissue classifica-
tion. An assessment of the hypoperfused area (expressed as
an average percentage of the short-axis LV surface area for
all perfusion slices) at rest and stress was performed and
compared to the hyperenhanced region on the corre-
sponding LGE-CMR short-axis slice.
Late Gadolinium Enhancement
Hyperenhancement on LGE-CMR was quantified on short-
axis LGE images using a semiautomatic method with
manual corrections where necessary [13].
Statistical Analysis
Calculations and statistics were performed using Graph Pad
Prism 5.0 software (Graph Pad Software, Inc., La Jolla,
CA, USA). Results are expressed as median and range. The
Kruskal–Wallis test with Dunn’s post hoc test was used to
compare global LV parameters, regional wall thickness,
fibrosis and myocardial perfusion between different groups
and myocardial segments. Differences in upslope ratio
corrected for LV arterial signal input was used to differ-
entiate myocardial segments that were either LVH-
LGE-, LVH?LGE- or LVH?LGE?. Differences with a
P\ 0.05 were considered statistically significant.
Results
Study Population Characteristics
Thirty-six young subjects were included: 12 patients with
HCM [20 (12–30) years, two females], 15 subjects at risk
of HCM [18 (14–26) years, seven females] and nine con-
trols [21 (16–30) years, two females]. Patient characteris-
tics are listed in Table 1. Genetic testing for known HCM
mutations was available in eleven patients with HCM and
revealed three patients with MYH7, three with MYBPC3
and one with TCAP, and in four subjects, no HCM muta-
tion was found. In the HCM-risk group, eight subjects
performed genetic testing (four MYBPC3, one TNNT2 and
no HCM mutation was found in three subjects).
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Left Ventricular Hypertrophy
No areas of LVH were found in the control or HCM-risk
group. LVH was found in all HCM patients, most fre-
quently in the basal and/or midventricular anteroseptal
(n = 11 patients) and inferoseptal wall (n = 9 patients).
Regional Myocardial Perfusion and Fibrosis
In one HCM patient and one HCM-risk subject, no ade-
nosine was administered due to the inability of securing an
intravenous access in place and allergic asthma, respec-
tively. Both were therefore excluded from the perfusion
analysis. In three HCM patients and three HCM-risk sub-
jects, only two short-axis perfusion slices were acquired
due to high heart rate. Segments with a large mismatch
between rest and stress images and segments with apparent
artefacts were excluded (25 segments out of 510 in total).
Figure 1 shows representative perfusion images at rest
and stress as well as corresponding LGE images in all three
groups. No perfusion deficits were observed in HCM-risk
subjects or in normal controls. In two HCM patients (18 %)
a perfusion deficit was found at rest and in eight patients
(73 %) during adenosine. One of these patients showed
hypoperfusion during adenosine without any LGE in any
segment with hypertrophy, i.e., only LVH?LGE- seg-
ments. The remaining patients with perfusion deficits
(n = 7) had at least one LVH?LGE? segment.
No hyperenhancement on LGE was present in HCM-risk
subjects or controls. Eight HCM patients (73 %) showed
hyperenhancement on LGE with a median of 2.9 (0.5–12)
% scar of LVM. Of these, seven patients also had hypop-
erfused myocardium during adenosine. In one patient, the
basal area with LVH?LGE? was not obtained during
perfusion imaging and no hypoperfused areas were visible
in the LVH-LGE- slices.
Perfusion Reserve Index
Semiquantitative analysis of perfusion expressed as the
ratio between upslope of stress and rest perfusion is shown
in Fig. 2. Analysis on a segmental level in HCM patients
showed that LVH?LGE- segments had decreased perfu-
sion (median, range) compared to LVH-LGE- segments
[1.5 (1.1–2.3) vs. 2.0 (1.8–2.6), P\ 0.001, n = 26 and
n = 96 segments, respectively]. Segments with LVH?
LGE? showed even lower perfusion [0.9 (0.6–1.8), n = 27
segments] compared to LVH?LGE- segments
(P\ 0.05). When performing the analysis on a per-patient
basis with segments averaged all differences remained
statistically significant except the comparison between
LVH?LGE- (n = 10 patients) and LVH?LGE? (n = 6
patients, P = ns). There was no significant difference
between HCM-risk subjects and LVH-LGE- segments in
HCM patients compared to controls [2.2 (1.4–4.5), 2.0
(1.8–2.6) vs. 2.1 (1.8–3.2), P = ns]. However, both
LVH?LGE- and LVH?LGE? segments in HCM
patients had lower perfusion compared to controls
(P\ 0.001).
Hypoperfused Areas Compared to Hyperenhancement
on LGE-CMR
The area of hypoperfused myocardium in HCM patients
during adenosine [20 (0–48) % slice area] was larger
compared to rest [0 (0–2) % slice area, P\ 0.001; Fig. 3.]
and was in all patients larger compared to the area of
hyperenhancement on LGE [4 (0–7) % slice area,
P\ 0.05]. There was no significant difference between
hypoperfused areas at rest and areas with LGE (P = ns). In
all but one patient, areas with LGE were located in
hypertrophied myocardium and within hypoperfused areas.
The remaining patient had both areas with hypoperfusion
exceeding areas with hyperenhancement on LGE, and LGE
Table 1 Subject characteristics
Controls (n = 9) HCM-risk (n = 15) HCM (n = 12)
Age (years) 21 (16–30) 18 (14–26) 20 (12–30)
Females, n (%) 2 (22 %) 7 (47 %) 2 (17 %)
b-blockers, n 0 0 4
End-diastolic volume/BSA (ml/m2) 101 (91–127) 92 (72–107) 91 (61–131)
End-systolic volume/BSA (ml/m2) 42 (38–63) 37 (29–49) 33 (23–84)*
Ejection fraction (%) 57 (42–63) 57 (52–66) 62 (36–77)
LVM/BSA (g/m2) 59 (37–74) 46 (37–56) 65 (43–158)
Interventricular septum thickness (mm) 10 (6–11) 9 (7–11) 17 (14–36)*,
Posterior wall thickness (mm) 8 (5–9) 7 (5–8) 8 (7–16)
All values are expressed as median (range)
* P\ 0.05 compared to controls;  P\ 0.05 compared to HCM-risk
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in the lateral wall with a borderline hypertrophied wall
(12–13 mm) without a perfusion defect (Fig. 4).
Discussion
This study indicates that young patients with HCM have
regional stress-induced ischemia in hypertrophied myo-
cardium. Perfusion during adenosine was even further
decreased in myocardial segments with both hypertrophy
and fibrosis compared to non-fibrotic hypertrophied seg-
ments. The extent of stress-induced hypoperfusion was
larger compared to fibrosis, suggesting that ischemia may
play a primary role in the pathogenesis of fibrosis in HCM.
Young subjects at risk of HCM showed no difference in
myocardial perfusion compared with controls.
Comparison to Earlier Work
In the current study, we found lower perfusion in segments
with LVH?LGE- and even lower perfusion in
LVH?LGE? segments, which, to our knowledge, has
Fig. 1 Short-axis first-pass
perfusion images of the left
ventricle at rest (left column),
adenosine stress (middle




column) in one patient with
hypertrophic cardiomyopathy
(HCM), one HCM-risk subject
and in one healthy control. In
the HCM patient, the extent and
severity of hypoperfused areas
(white dashed line) were larger
at adenosine stress compared to
rest. The extent of hypoperfused
areas at adenosine stress was
also larger compared to fibrosis
on LGE-CMR (yellow line),
suggesting ischemia as the
precursor of fibrosis. Green
line = epicardium, red
line = endocardium
Fig. 2 Regional myocardial perfusion expressed as upslope ratio
(median, range) in normal controls, patients at risk of hypertrophic
cardiomyopathy (HCM-risk) and HCM patients. All subjects were
subdivided into three groups based on morphology: (1) LVH-LGE-:
segments without left ventricular hypertrophy (LVH) and fibrosis
(LGE), (2) LVH?LGE-: segments with LVH but without fibrosis
and (3) LVH?LGE?: segments with LVH and fibrosis. There was a
significant difference between the LVH-LGE- segments compared
to both LVH?LGE- and LVH?LGE? segments in HCM patients.
Segments that were LVH?LGE? had lower perfusion than
LVH?LGE- segments and were statistically significant on segmen-
tal analysis but not averaged on a per-patient basis. No difference in
regional perfusion was seen between HCM-risk subjects and controls.
*P\ 0.05, ***P\ 0.001 per-patient analysis; P\ 0.05, 
P\ 0.001 on segmental analysis
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previously not been reported in young HCM patients. In
cohorts with older HCM patients, similar degree of
hypoperfusion in areas with LVH was found regardless of
the presence of fibrosis [17, 21, 32, 34, 37]. We have
previously shown global hypoperfusion using flow mea-
surements in the coronary sinus in young HCM patients
[12]. The present study extends these results, showing that
regional hypoperfusion is linked to both LVH and fibrosis.
The perfusion deficits ranged from subendocardial to
transmural, but fibrosis was predominantly found in the
mid-mural and in hypertrophied segments, similar to pre-
vious studies [7, 30]. Our results with the perfusion deficits
mainly manifesting at adenosine stress show the impor-
tance and added value of performing myocardial perfusion
at both rest and stress [21, 32, 34, 37].
We did not find a difference in perfusion between HCM-
risk subjects and normal controls, which supports our
previous findings on global perfusion [12]. Genotype-pos-
itive subjects with no sign of HCM morphology at age 18
have been shown to have a more benign clinical course
[10]. Demonstrating a normal perfusion during adenosine
stress may provide a more sensitive and accurate way to
correctly classify these subjects as true phenotype negative
as compared to only wall thickness. This remains to be
proven by further studies.
Pathophysiology of Fibrosis in HCM
The cause and timeline of fibrosis development in HCM is
still somewhat unclear. LGE on CMR results from an
expansion of extracellular volume in the myocardium [3]
and may be caused by edema, necrosis or fibrosis, which all
can occur in HCM patients [1, 27]. LGE on CMR has been
shown to correlate with fibrosis on histopathology in HCM
[23, 31]. In the current study, the hypoperfused area was
larger and more severe at adenosine stress compared to
both rest perfusion and to the extent of fibrosis in corre-
sponding slices. Our findings suggest that replacement
fibrosis is driven by ischemia in the hypertrophied LV, with
the assumption that LGE represents fibrosis. This finding
that ischemia precedes the development of replacement
fibrosis is also supported by other studies using CMR [17,
21, 29, 32, 34, 37] and positron emission tomography
(PET) [5, 36]. Histologic features of HCM such as myocyte
disarray, intramural arteriolar dysplasia [4, 24, 27], inter-
stitial fibrosis [23, 31] and a lower capillary density [20]
within the hypertrophied myocardial segments demonstrate
the pathophysiological substrates for ischemia.
Others, however, have shown data supporting that
fibrosis is primary in HCM. In a histopathological study,
Varnava et al. [38] found poor correlation between
Fig. 3 Areas of hypoperfusion in HCM patients at rest, adenosine
stress and fibrosis determined as hyperenhancement on LGE-CMR
expressed as an average % of slice area in all patients with HCM.
Areas of hypoperfusion at adenosine stress are significantly larger
than hypoperfused areas at rest and fibrotic areas. Black trian-
gles = three patients overlapping with no perfusion deficits or fibrosis
on LGE. *P\ 0.05, ***P\ 0.001
Fig. 4 Short-axis first-pass perfusion images of a HCM patient at rest
(left column), adenosine stress (middle column) and corresponding
late gadolinium enhancement (LGE)-CMR image for determining
fibrosis (right column), demonstrating two areas with hypoperfusion
at stress perfusion. Interestingly, the area within the lateral wall (white
arrow) shows a larger area of fibrosis (yellow line) than apparent
hypoperfusion (dashed white line). This may be a display of fibrosis
pathology of a different etiology. Green line = epicardium, red
line = endocardium
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myocyte disarray and small vessel disease with the pres-
ence of fibrosis. Furthermore, there is preclinical evidence
suggesting that pathways involved in fibrosis and collagen
deposition are activated in HCM before the onset of
pathological evidence of disease [22]. In a clinical study,
Ho et al. [15] confirmed these preclinical findings when
showing that biomarkers of an increased collagen I syn-
thesis in the myocardium is present in genotype-positive
HCM-risk individuals with normal wall thickness without
LGE. Thus, the authors argued that fibrosis in HCM may
be a direct consequence of sarcomere mutations and not
due to ischemia. However, in this study, perfusion imaging
was not performed. Bravo et al. [5] and Soler et al. [35]
have shown, in subsets of their populations, presence of
LGE in regions with normal perfusion, with [5] and even
without LVH in HCM patients [35]. In our study, we also
found one patient with fibrosis and no evidence of ischemia
in a lateral wall with borderline hypertrophy (Fig. 4). In the
hypertrophied inferior and inferoseptal wall of the same
patient, a clear area of hypoperfusion at stress was visible
with fibrosis in the same area within the hypoperfused area.
This split image could represent two different pathophys-
iological explanations for fibrosis in HCM [5].
Clinical Implications and Further Directions
This study in young patients with HCM showed the benefit
of performing a CMR scan to assess function, fibrosis and
perfusion with adenosine stress, in the same session.
However, in the current European Society of Cardiology
guidelines [9], CMR with LGE for assessment of anatomy,
function and fibrosis only has a class IIa recommendation
(evidence level B), whereas transthoracic echocardiogra-
phy for measurement of diastolic wall thickness has a class
I recommendation (evidence level C). Furthermore, pres-
ence of fibrosis on CMR has modest prognostic implica-
tions [11, 18] and data on the prognostic value of areas
with increased extracellular volume (ECV) on T1-mapping
are lacking. There is currently no mention of perfusion
imaging on CMR in HCM in guidelines [9], but HCM
patients with ischemia have been shown to have a worse
clinical outcome [6].
In the current study, regional perfusion imaging
demonstrates pathology beyond LVH and LGE. Thus,
ischemia on CMR as demonstrated in the current study
may have the potential to be an earlier biomarker of disease
in HCM [17, 29, 32]. This will be elucidated further in the
current cohort in an upcoming 3-year follow-up study.
However, there is a need for larger clinical prospective
studies to evaluate whether adenosine perfusion is a suffi-
ciently strong predictor of disease severity and progression
to alter clinical management.
Limitations
The study population is small, and the study was therefore
not powered sufficiently to detect small differences in
perfusion indices between HCM-risk and controls. How-
ever, the HCM patient population was sufficient to detect
differences in perfusion between different regions in the
myocardium. All patients and subjects at risk did not want
to undergo genetic testing, thus making comparison
between genotypes and CMR indices difficult.
Conclusions
In summary, this study conducted in young asymptomatic
HCM patients has demonstrated a clear relationship
between regional ischemia and myocardial hypertrophy,
with further decrease in myocardial perfusion in hyper-
trophied segments with signs of fibrosis. Regional
myocardial perfusion did, however, not discriminate
between HCM-risk subjects and controls. Furthermore, the
area of stress-induced ischemia exceeded the fibrosis,
suggesting that development of replacement fibrosis is
being preceded by ischemia. Adenosine perfusion imaging
may aid in the risk stratification of young HCM patients;
however, there is a need for larger prospective studies to
show the clinical impact.
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